Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.33 |
| ▸ | HPGD | P15428 | 7/20 | 0.33 |
| ▸ | CRHBP | P24387 | 2/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6928593 | 0.83 | GAA (0.35) | GAALMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6928339 | 0.83 | KDM4E (0.43) | GAALMNAKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL6925081 | 0.83 | GAA (0.48) | GAALMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7248344 | 0.73 | DAO (0.57) | GAAKDM4EMAPTALDH1A1KMT2A | |
| SCHEMBL6925463 | 0.70 | KDM4E (0.42) | GAALMNAKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL18430426 | 0.69 | KDM4E (0.47) | GAALMNAKDM4EMAPTRXFP1 | |
| SCHEMBL6920019 | 0.68 | LMNA (0.41) | GAALMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6924855 | 0.68 | GAA (0.43) | GAALMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29108983 | 0.68 | ALDH1A1 (0.51) | GAALMNAKDM4EMAPTRXFP1 | |
| SCHEMBL3610681 | 0.67 | KDM4E (0.42) | GAALMNACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020037915-A1 | Compounds and compositons for treating C1s-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037915-A1 | Compounds and compositons for treating C1s-mediated diseases and conditions | C1S, C1R, C9 | GAA 2994/4885LMNA 560/4885CYP1A2 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.